MULTIPLE MYELOMA

Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse effects in relapsed/refractory multiple myeloma (RRMM).

Panelists discuss how the KarMMa-3 trial demonstrated superior efficacy of idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy compared to standard treatment regimens in patients with heavily pretreated, triple-class–exposed relapsed/refractory multiple myeloma (RRMM).

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Panelists discuss how to select optimal therapy for a 66-year-old patient with early relapse following autologous stem cell transplantation (ASCT), considering factors such as prior treatment exposure, duration of response, and emerging therapeutic options including cellular therapies.

Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, infections, and neurotoxicity, to optimize long-term patient outcomes and safety.

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.

The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after suboptimal first-line therapy.

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in lenalidomide-refractory multiple myeloma.

Panelists discuss how to manage an aggressive case of early posttransplant progression in a young woman with functionally high-risk multiple myeloma (MM), focusing on rapid intervention strategies and novel therapeutic approaches to overcome poor prognosis disease.

Panelists discuss how to approach treatment selection and sequencing for a 58-year-old woman with high-risk multiple myeloma (MM) who has developed progressive disease after stem cell transplantation, considering factors such as prior therapy exposure, available options, and disease biology.

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma.

The FDA has accepted the resubmitted biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma in heavily pretreated adults.

Panelists discuss how to optimize maintenance therapy following autologous stem cell transplantation by evaluating factors such as duration, drug selection, and risk-adapted approaches to maximize long-term outcomes in multiple myeloma patients.

Panelists discuss how the paradigm in transplant-eligible newly diagnosed multiple myeloma (NDMM) has shifted to considering which patients should not receive quadruplet CD38-containing regimens rather than who should, given the compelling efficacy data supporting this approach.

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR T-cell therapy while carefully monitoring for and managing toxicities through established protocols. Key considerations include implementing systematic toxicity management strategies, maintaining long-term patient monitoring, and staying informed about emerging therapeutic options. The field is evolving with promising novel agents and combination approaches being investigated, particularly for patients who progress after initial treatments.

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), potentially establishing a new standard of care in this setting.

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) by considering factors such as efficacy data, toxicity profiles, and individual patient characteristics.

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but with some differences from clinical trials. Ide-cel demonstrates effectiveness in patients with prior BCMA exposure, though responses may be impacted. Compared with standard of care (SOC), both ide-cel and cilta-cel show superior outcomes in terms of response rates and progression-free survival, though long-term data are still emerging in real-world settings.

The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed R/R MM, with a median progression-free survival of 13.3 vs 4.4 months and an overall response rate of 71% vs 42%. The favorable safety profile and significant survival benefit support ide-cel as a preferred option for third-line and greater treatment, particularly in patients with good performance status who can tolerate bridging therapy.

Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant-eligible newly diagnosed multiple myeloma (NDMM) through assessment of disease characteristics, patient factors, and available therapeutic options.

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), highlighting its potential as a new treatment standard.

Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Ashraf Z. Badros, MB, ChB, discusses the background, methods, and design of the phase 3 AURIGA trial.